Localized GI drug delivery / Gastrointestinal therapeutics
Strategic Profile
Eupraxia develops EP-104IAR for intra-articular injections for osteoarthritis and EP-104GI for submucosal injections in the GI tract for indications such as eosinophilic esophagitis. The company completed a $63.2 million public offering in February 2026 and is well-capitalized into H2 2028 with over $140 million cash.
Cyborg Score Rationale
Eupraxia has validated clinical data supporting its lead candidate, a well-defined pipeline targeting underserved indications, and sufficient capital runway into 2028. However, as a clinical-stage company with no approved products, execution risk remains significant, and the company faces typical biotech development challenges.
Top Insights
(May 2026) Robust Phase 1b/2a data from EP-104GI in EoE showing tissue health and symptom improvement after single treatment at 36 weeks
(February 2026) Raised $63.2 million in public offering to fund expanded clinical trials of EP-104GI in additional GI indications
(May 2026) Phase 2b placebo-controlled trial enrollment initiated with topline results expected in H2 2026
Dual-indication strategy with EP-104IAR for osteoarthritis and EP-104GI for GI disorders leveraging common platform technology
Named Competitors
KENALOG — Corticosteroid injection for various indications including EoE off-label use
Dupilumab — Systemic biologic approved for EoE
ADLONBIO — Developing local GI therapeutics for EoE and related conditions
Recent Developments
(May 2026) Reported positive nine-month clinical data from Phase 1b/2a RESOLVE trial in EP-104GI for eosinophilic esophagitis
(February 2026) Completed $63.2 million public offering to fund EP-104GI trials in additional indications
(June 2026) Announced presentation at investor conferences including Bloom Burton Healthcare Investor Conference
Open the full interactive Eupraxia Pharmaceuticals Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.